Compugen expands intellectual property portfolio for COM701 with new U.S. patent covering combination use with anti-PD-1 antibody
Tuesday, July 16, 2019 | DrugName : COM-701 Compugen Ltd., a clinical-stage cancer immunotherapy company and leader in predictive target
Read More